Wells Fargo’s BioMarin Pharmaceuticals BMRN Stock Holding History

Wells Fargo’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-14,400	Closed	-$1.26M	–	6941
2024 Q1	$1.26M	Hold	14,400	–	–	﹤0.01%	3302
2023 Q4	$1.39M	Buy	+14,400	New	+$1.27M	﹤0.01%	3192
2023 Q2	–	Sell	-223,200	Closed	-$21.7M	–	7592
2023 Q1	$21.7M	Buy	223,200 +203,200	+1,016%	+$21.1M	0.01%	1080
2022 Q4	$2.07M	Buy	+20,000	New	+$1.88M	﹤0.01%	2757
2022 Q1	–	Sell	-100	Closed	-$9K	–	7073
2021 Q4	$9K	Sell	100 -47,100	-100%	-$3.89M	﹤0.01%	6569
2021 Q3	$3.65M	Hold	47,200	–	–	﹤0.01%	3132
2021 Q2	$3.94M	Buy	+47,200	New	+$3.74M	﹤0.01%	3071
2021 Q1	–	Sell	-25,900	Closed	-$98K	–	6894
2020 Q4	$98K	Buy	25,900 +8,600	+50%	+$682K	﹤0.01%	5365
2020 Q3	$50K	Hold	17,300	–	–	﹤0.01%	5511
2020 Q2	$589K	Hold	17,300	–	–	﹤0.01%	4202
2020 Q1	$167K	Hold	17,300	–	–	﹤0.01%	4782
2019 Q4	$175K	Hold	17,300	–	–	﹤0.01%	5029
2019 Q3	$68K	Buy	+17,300	New	+$1.33M	﹤0.01%	5461

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wells Fargo's BMRN Position: Q1 2026 in Review

Wells Fargo increased its BioMarin Pharmaceuticals (BMRN) stake by 6.7% in Q1 2026, buying an estimated $124K and bringing the position to 33,775 shares worth $1.91M. The position accounts for ﹤0.01% of the portfolio, ranked #3309.

Wells Fargo first reported a position in BMRN in Q2 2013 and has held it in 52 quarters since. The position peaked at $272M in Q4 2015. 555 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

Wells Fargo held 33,775 shares of BioMarin Pharmaceuticals worth $1.91M as of Q1 2026.
Wells Fargo bought 2,119 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $124K.
BioMarin Pharmaceuticals made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #3309 holding.
Wells Fargo first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
Wells Fargo's BioMarin Pharmaceuticals position peaked at $272M in Q4 2015.
555 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.